Titlebook: Comparative Effectiveness in Surgical Oncology; Key Questions and Ho Karl Y. Bilimoria,Christina A. Minami,David M. Mah Book 2015 Springer

絆住

IRS

0927-3042 siderablecost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to addres978-3-319-37868-8978-3-319-12553-4Series ISSN 0927-3042 Series E-ISSN 2509-8497

FECT

https://doi.org/10.1007/978-3-322-95109-0therapy provides better outcomes compared to surgery alone for esophageal, GEJ, and gastric cancers. Studies indicate a trend towards improved survival when neoadjuvant chemoradiotherapy is compared to chemotherapy alone. When patients have undergone resection with node-positive disease without rece

BROOK

花費

Book 2015rials are not always feasible owing to the impracticality of conducting the trial, the considerablecost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to addres

negligence

Comparative Effectiveness in Esophagogastric Cancer,therapy provides better outcomes compared to surgery alone for esophageal, GEJ, and gastric cancers. Studies indicate a trend towards improved survival when neoadjuvant chemoradiotherapy is compared to chemotherapy alone. When patients have undergone resection with node-positive disease without rece

傻瓜

Comparative Effectiveness in Hepatic Malignancies,actice lacking. Indeed, many of the current treatment recommendations for the management of liver malignancies are based primarily on retrospective data. We herein review select CER issues concerning select decision-making topics in the management of liver malignancies.

Conscientious

公司

Leveraging Comparative Effectiveness Research to Improve the Quality of Multidisciplinary Care for e resulted in dramatic improvements in oncologic outcomes for this disease. However, not every question pertinent to breast cancer is amenable to such efficacy trials. This chapter will discuss some of the unique aspects of breast cancer that make efficacy RCTs challenging and/or impractical, how co

無力更進